Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term mTOR. Found 14 abstracts

Jung K, Kang H, Mehra R. Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers of the head & neck. 2018 Jan;3:3.   PMCID: PMC6460806
Al-Ashmawy AA, Ragab FA, Elokely KM, Anwar MM, Perez-Leal O, Rico MC, Gordon J, Bichenkov E, Mateo G, Kassem EM, Hegazy GH, Abou-Gharbia M, Childers W. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kalpha/mTOR inhibitors. Bioorganic & medicinal chemistry letters. 2017 Jul 15;27(14):3117-22.
Gokare P, El-Deiry WS. The tuberous sclerosis complex gets fatter. Oncotarget. 2017 Jun 27;8(26):41780-1.   PMCID: PMC5522022
Michael JV, Wurtzel JG, Goldfinger LE. Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment. Anticancer research. 2016 Oct;36(10):5053-61.
Wang X, Li M, Gao Y, Gao J, Yang W, Liang H, Ji Q, Li Y, Liu H, Huang J, Cheng T, Yuan W. Rheb1-mTORC1 maintains macrophage differentiation and phagocytosis in mice. Exp Cell Res. 2016 Jun 10;344(2):219-28.
Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Current oncology reports. 2015 Dec;17(12):58.
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Kung CP, Budina A, Balaburski G, Bergenstock MK, Murphy ME. Autophagy in Tumor Suppression and Cancer Therapy. Critical Reviews in Eukaryotic Gene Expression. 2011 Jan;21(1):71-100.   PMCID: PMC3187613
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy. 2010 Oct;10(7):658-64.   PMCID: PMC3093809
Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP, Guan KL. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO Journal. 2007 Nov;26(23):4812-23.
Robb VA, Astrinidis A, Henske EP. Frequent of ribosomal protein S6 hyperphosphorylation in lymphangioleiomyomatosis-associated angiomyolipomas. MODERN PATHOLOGY. 2006 Jun;19(6):839-46.
Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homolog enriched in brain. Cancer Research. 2006 Jan;66(19):9461-6.
Altomare DA, You HH, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005 Sep 08;24(40):6080-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term mTOR

mTOR rapamycin AKT p53 tuberous sclerosis chloroquine Pik3ca Rheb gene mammalian target Egfr tyrosine kinase inhibitor beta-catenin endothelial cisplatin 2-d]pyrimidine Pyrido[3 p70 S6 kinase Pten renal angiomyolipomas TUBEROUS SCLEROSIS metastatic colorectal-cancer Mammary gland RCC activation therapeutic target bladder cancer Everolimus mouse model isolated rat Akt Pazopanib epigenetics growth-factor chemotherapy ovarian hepatocytes kidney cancer tsc2 therapeutic strategy Erk in-vitro RHEB Akt kinase pathway in breast cancer cell proliferation) genetics Precision medicine Rheb1 receptor PROTEIN-KINASE Tsc gene-expression progression Hpv lysosomes interacting factor-i unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (TSC2 (tuberous sclerosis complex 2) antitumor-activity Erbb3 estrogen tuberin Rheb mTOR kinase pathway breast cancer protooncogene platinum-resistant Phosphorylation Erbb2 3-d]pyrimidine phosphoinositide Pyrido[2 Bevacizumab breast-cancer bcl-x-l Pi3k refractory angiomyolipomas 1981 ole b-v90-p665 asbestos endosomes Nature remains neutral with regard to jurisdictional claims in published maps and mesothelioma malignant glioma-cells Human Signal transduction (estrogen-induced activation of TSC unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (eIF-4E-BP1 (eIF-4E-binding protein 1)-phosphorylation of met phosphatidylinositol 3-kinase apoptosis Ovarian clinical trial lymphangiomyomatosis resistant prostate-cancer Copy number abnormality PI3K pathway cancer expression Phagocytosis tuberous sclerosis complex Ras hypoxia-inducible factor-1 akt activation 1989 donnell tj-v57-p79 GENE-PRODUCTS kinase RAPAMYCIN radical cystectomy tumor suppressor unclassified) Ribosomal proteins Role: BSU (Biological study-BIOL (Biological study) (S6 Circulating tumor cells INDUCED Cell proliferation 3-Kinase alpha factor scatter factor disease cholesterol 3-kinase complexes 1989 ser a-v129-p740 3bdo drosophila fat-body signaling pathways ovarian-cancer Dovitinib Mutation unclassified) Estrogens Role: BSU (Biological study-BIOL (Biological study) (estrogen-induced activation of TSC tumor-suppressor kinase-b carcinoma patients Sunitinib peripheral-blood betaine homocysteine methyltransferase Dual inhibitor Hnscc malignant pleural mesothelioma prostate intraepithelial neoplasia Cetuximab oncogene inhibition MAMMALIAN TARGET pulmonary lymphangioleiomyomatosis institutional affiliations S6 MAP c-met autophagy Beclin-1 Chemotherapy PHOSPHORYLATION unclassified) G proteins Role: BSU (Biological study-BIOL (Biological study) (RHEB (Ras homolog enriched in brain) Drug resistance phosphatidylinositol GAP ACTIVITY protein conjugation system lymphangioleiomyomatosis 2008 nida i-v445-p77 Pathology galectin inhibitor dual inhibition
Last updated on Friday, August 07, 2020